As this analysis shows, contract manufacturing organizations (CMOs) can play an important role in the biotech industry and
can help create a potentially valuable investment. Based on our research, the CMO market is relatively undeveloped, especially
in mammalian cell technologies, and represents a significant opportunity. However, sizable capital requirements and long set-up
times for a manufacturing plant to begin operations often create barriers to entering this market.
However, we believe that a company with significant financial clout, an appetite and ability to take on risk, and the reputation
and ability to recruit top talent, can be well positioned to lead the biologics CMO market. With adequate scale and superior
operations, such a company could very well dominate the CMO market and potentially realize high economic returns.
Jayant Lakshmikanthan is a senior consultant at Deloitte Consulting LLP, 415.783.5288, email@example.com
1. Ransohoff TC, Mittendorff II RE, Levine HL. Forecasting industrywide capacity requirements. In: Advances in Large-Scale
Biopharmaceutical Manufacturing and Scale-Up Production. Washington, DC: ASM Press and the Institute for Science and Technology
Management; 2004 Oct.
2. Business Insights. The biogeneric market outlook: an analysis of market dynamics, growth drivers and leading players.
Rockville, MD:Business Insights; 2005.
3. Tulsi B. Bugs punch the clock as next protein manufacturers. Drug Discov Devel. 2004 Jun.
4. Citigroup report. Lonza Group AG. London: Citigroup: 2005 Sept.
5. CIBC World Markets Biotechnology Coverage Universe, 2005.
6. Malik A, Pinkus G, Sheffer S. BioPharma: capacity crunch. McKinsey Quarterly, 2002 Aug 17;#2 special edition: Risk and